Table 2 Descriptive parameters of the resistant patients
From: Predictors of dopamine agonist resistance in prolactinoma patients
Sex | Baseline PRL (μg/l) | Age at diagnose (range in years) | Symptoms (*) | Mass effects | Tumour classification | Tumour volume (cm3) | Cystic/ Necrotic/ hemorragic component | Surgery | Sclerosis |
|---|---|---|---|---|---|---|---|---|---|
Man | 668.67 | 20–30 | Sexual dysfunction | Headache/ Dizziness | Macroadenoma | 3.34 | Yes | Yes | Yes |
Woman | 126.9 | 20–30 | Menstrual disturbances | None | Macroadenoma | 3.33 | Yes | No | / |
Woman | 77,2 | 20–30 | Menstrual dysfunction + galactorrhea | Visual defects | Microadenoma | Not known | Not known | Yes | No |
Man | 1058.3 | 50–60 | None | Headache/ Dizziness | Macroadenoma | 6.93 | Yes | Yes | Yes |
Man | 230.65 | 60–70 | Sexual dysfunction | Headache/ Dizziness | Macroadenoma | 2.041 | No | No | / |
Man | 253.77 | 30–40 | Sexual dysfunction | None | Macroadenoma | 1.23 | Yes | Yes | Yes |
Man | 332.43 | 20–30 | Menstrual dysfunction | None | Macroadenoma | 41.36 | No | Yes | Yes |
Woman | 2582.3 | 60–70 | None | Visual defects | Macroadenoma | 2.65 | No | No | / |
Woman | 131.0 | 50–60 | Menstrual dysfunction | None | Microadenoma | Not known | Not kown | Yes | Yes |
Woman | 90.19 | 40–50 | Menstrual dysfunction | None | Macroadenoma | Not known | Yes | No | / |
Woman | 162.0 | 20–30 | Menstrual dysfunction + galactorrhea | None | Macroadenoma | Not known | Yes | No | / |